Monday 05 October 2026
Internal Reference Number: FOI_9615
Date Request Received: 18/08/2026 00:00:00
Date Request Replied To: 09/09/2026 00:00:00
This response was sent via: By Email
Request Summary: Multiple Myeloma
Request Category: Companies
| Question Number 1: I have a freedom of information request regarding the treatment of Multiple Myeloma. Could you please answer the following questions. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. | |
| Answer To Question 1: . 106 | |
| Question Number 2: Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] • Bortezomib [Velcade] + Dexamethasone • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Daratumumab [Darzalex] monotherapy • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) • Lenalidomide [Revlimid] + Dexamethasone • Lenalidomide [Revlimid] monotherapy • Panobinostat + Bortezomib + Dexamethasone • Pomalidomide [Imnovid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] | |
| Answer To Question 2: Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] - less than 5 • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone - less than 5 • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone - 0 • Bortezomib [Velcade] - 0 • Bortezomib [Velcade] + Dexamethasone - 0 • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) - VCD less than 5 patients but this doesn’t match the drugs listed • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) - 0 • Carfilzomib [Kyprolis] + Dexamethasone - 0 • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) - less than 5 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) -12 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) - 8 • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) - 20 • Daratumumab [Darzalex] monotherapy - 0 • Elranatamab - 6 • Idecabtagene vicleucel [Abecma] - 0 • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) - 9 • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) - 5 • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) - 7 • Lenalidomide [Revlimid] + Dexamethasone - 0 • Lenalidomide [Revlimid] monotherapy - 33 • Panobinostat + Bortezomib + Dexamethasone - 0 • Pomalidomide [Imnovid] + Dexamethasone - less than 5 • Selinexor + Bortezomib [Velcade] + Dexamethasone - 0 • Selinexor + Dexamethasone - 0 • Talquetamab - less than 5 • Teclistamab [Tecvayli] - 0 • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] - 7 total less than 5 venetoclax, 5 melphalan, less than 5 VDT PACE | |
| Question Number 3: In the last 6 months, how many patients have been initiated* on the following regimens? • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Lenalidomide [Revlimid] monotherapy • Lenalidomide [Revlimid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. | |
| Answer To Question 3: In the last 6 months, how many patients have been initiated* on the following regimens? • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone less than 5 • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0 • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0 • Carfilzomib [Kyprolis] + Dexamethasone 0 • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) 0 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) less than 5 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) less than 5 • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) less than 5 • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 9 • Lenalidomide [Revlimid] monotherapy less than 5 • Lenalidomide [Revlimid] + Dexamethasone 0 • Selinexor + Bortezomib [Velcade] + Dexamethasone 0 • Selinexor + Dexamethasone 0 • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] 12 patients, 5 melphalan, less than 5 each for elranatamab, IRD, IsaPomDex, PomDex, VDT PACE *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. | |
| Question Number 4: In the last 6 months, how many patients have received the following second-line treatment? • Lenalidomide [Revlimid] + Dexamethasone | |
| Answer To Question 4: 0 | |
| Question Number 5: Does your trust participate in any clinical trials for multiple myeloma? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 5: Salisbury NHS Foundation Trust is currently participating in 1 clinical trial for multiple myeloma: Myeloma XIV (FiTNEss) - 9 patients taking part | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
